Skip to main content
Dryad

Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis

Data files

Sep 01, 2022 version files 241.02 KB

Abstract

This dataset was the minimal dataset of the research article entitle 'Safety of ChAdOx1 nCoV-19 vaccination in patients  with end-stage renal disease on hemodialysis'.  The study aims to investigate the localized and systemic adverse effects (AEs) within 30-days after the first dose of ChAdOx1 nCoV19 (Oxford-AstraZeneca) vaccination in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). The first dataset is the raw data for logistic regression analyses examining the risk factors in association with AEs, another dataset  contains the second- and the seventh- day incidences of various AEs depicted in bar graphs. It comprises variables recording the status of patient-reported local and systemic AEs in questionnaire on the second and seventh days after vaccination as well as patients' baseline demographic and clinical characteristics.